Target intelligence / Profile preview

40S ribosomal protein SA (High-affinity laminin receptor) (RPSA)

Target
RPSA
Molecular classification
Ribosomal protein, Non-integrin receptor, Cell surface protein
01

Overview

The High-affinity laminin receptor, also known as 40S ribosomal protein SA (RPSA) or the 37/67 kDa laminin receptor (37/67LR), is a multifunctional protein that serves as both a component of the 40S ribosomal subunit and a non-integrin cell surface receptor (UniProt P08865). On the plasma membrane, it facilitates high-affinity binding to laminin-1, a major component of the basement membrane, thereby regulating cell adhesion, migration, and signaling (PMID: 23536039). RPSA is frequently overexpressed in various malignant tumors, including breast, lung, and colorectal cancers, where its expression levels correlate with increased metastatic potential and poor clinical prognosis (PMID: 23536039, PMID: 21114738). Beyond its role in oncology, RPSA acts as a receptor for several human pathogens, including the cellular prion protein (PrPc), various viruses such as Dengue and Adeno-associated virus (AAV), and certain bacteria (PMID: 15107831). The protein's dual localization—cytoplasmic for translation and membrane-bound for extracellular interaction—makes it a unique but challenging therapeutic target. Therapeutic strategies targeting RPSA include the use of small molecules like epigallocatechin gallate (EGCG), which binds the receptor with high affinity, as well as monoclonal antibodies and siRNA to inhibit its pro-metastatic and pathogen-mediating functions (PMID: 21114738, PMID: 15107831). Current research also explores its role in neurodegenerative conditions like Alzheimer's disease, where it may interact with amyloid-beta peptides (PMID: 23536039).

Other names
37/67 kDa laminin receptorLAMR1Laminin-binding proteinp4067LR37LRPLaminin receptor 1
02

Mechanism of action

Competitive inhibition of laminin-1 binding to the extracellular domain, downregulation of surface receptor expression, and blockade of pathogen internalization pathways.

03

Biological functions

Cell-matrix adhesionProtein translationRibosome assemblySignal transductionCell migrationViral entryPrion protein binding
04

Disease associations

Cancer metastasisPrion diseasesViral infectionAlzheimer's disease
05

Safety considerations

Potential disruption of essential ribosomal protein synthesisRisk of systemic toxicity due to ubiquitous expression in healthy tissues
06

Interacting drugs

Epigallocatechin gallate

4 more in the full profile.

07

Biomarkers

RPSA protein expressionRPSA mRNA levels

Beyond the preview

Go deeper on 40S ribosomal protein SA (High-affinity laminin receptor) (RPSA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 40S ribosomal protein SA (High-affinity laminin receptor) (RPSA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call